Zepto Life Technology has been selected as one of six semi-finalists for the prestigious 2020 AACC Disruptive Technology Award. Zepto aims to revolutionize diagnostics by replacing traditional blood cultures with a rapid, point-of-care molecular diagnostic platform that identifies pathogen cell-free DNA directly from plasma.
Zepto’s innovative technology utilizes Giant Magnetoresistance (GMR), combining microarray and melting curve techniques to deliver unparalleled diagnostic accuracy. At the presentation, Zepto showcased its ability to detect multiple invasive fungal infections using GMR technology, which enables multiplexing to identify various pathogens simultaneously. The assay example highlighted the detection of nine fungal strains that account for 95% of fungal infections in the U.S.
About AACC’s Disruptive Technology Award Competition
AACC’s Disruptive Technology Award competition recognizes innovative testing and disruptive technology solutions that improve patient care through diagnostic performance or access to high quality testing.
To learn more about AACC’s Disruptive Technology Award: https://meeting.aacc.org/conference-program/disruptive-technology-award